Needham Remains a Buy on Autolus Therapeutics (AUTL)

Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics (AUTLResearch Report) today and set a price target of $12.00. The company’s shares opened today at $2.81.

According to TipRanks, Blum is an analyst with an average return of -24.0% and a 27.47% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $12.25 average price target, a 335.94% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Autolus Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $42.06 million. In comparison, last year the company earned a revenue of $1.51 million and had a GAAP net loss of $33.17 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Read More on AUTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More